Why are there no approved treatments for cognitive impairment in schizophrenia?
作者信息
Keefe Richard S E
机构信息
Department of Psychiatry, Duke University Medical Center, Durham, NC, USA.
出版信息
World Psychiatry. 2019 Jun;18(2):167-168. doi: 10.1002/wps.20648.
Abstract
摘要
相似文献
1
Why are there no approved treatments for cognitive impairment in schizophrenia?为什么精神分裂症的认知障碍没有得到批准的治疗方法？
World Psychiatry. 2019 Jun;18(2):167-168. doi: 10.1002/wps.20648.
2
Cognitive Impairment Associated with Schizophrenia: From Pathophysiology to Treatment.精神分裂症相关的认知障碍：从病理生理学到治疗
Annu Rev Pharmacol Toxicol. 2023 Jan 20;63:119-141. doi: 10.1146/annurev-pharmtox-051921-093250. Epub 2022 Sep 23.
3
The Use of Cognitive Screening in Pharmacotherapy Trials for Cognitive Impairment Associated With Schizophrenia.认知筛查在与精神分裂症相关的认知障碍药物治疗试验中的应用
Front Psychiatry. 2019 Sep 6;10:648. doi: 10.3389/fpsyt.2019.00648. eCollection 2019.
4
European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia.欧洲精神病学协会关于精神分裂症认知障碍治疗的指南。
Eur Psychiatry. 2022 Sep 5;65(1):e57. doi: 10.1192/j.eurpsy.2022.2315.
5
Should cognitive impairment be included in the diagnostic criteria for schizophrenia?认知障碍是否应纳入精神分裂症的诊断标准？
World Psychiatry. 2008 Feb;7(1):22-8. doi: 10.1002/j.2051-5545.2008.tb00142.x.
6
Premorbid intellectual ability in schizophrenia influence family appraisal related to cognitive impairments: a cross-sectional study on cognitive impairment and family assessments.精神分裂症患者的病前智力能力影响与认知障碍相关的家庭评估：一项关于认知障碍和家庭评估的横断面研究。
BMC Psychiatry. 2022 Mar 31;22(1):227. doi: 10.1186/s12888-022-03879-2.
7
How should DSM-V criteria for schizophrenia include cognitive impairment?《精神疾病诊断与统计手册》第五版中精神分裂症的标准应如何纳入认知障碍？
Schizophr Bull. 2007 Jul;33(4):912-20. doi: 10.1093/schbul/sbm046. Epub 2007 Jun 13.
8
Cognitive Deficit in Schizophrenia: From Etiology to Novel Treatments.精神分裂症中的认知缺陷：从病因到新疗法
Int J Mol Sci. 2021 Sep 14;22(18):9905. doi: 10.3390/ijms22189905.
9
Activators of α7 nAChR as Potential Therapeutics for Cognitive Impairment.α7烟碱型乙酰胆碱受体激动剂作为认知障碍的潜在治疗药物
Curr Top Behav Neurosci. 2020;45:209-245. doi: 10.1007/7854_2020_140.
引用本文的文献
1
Assessing the Effect of Food on the Pharmacokinetics of Iclepertin in Healthy Volunteers: A Phase I, Open-Label, Randomised, Cross-over Trial.评估食物对健康志愿者中艾考替普汀药代动力学的影响：一项I期、开放标签、随机、交叉试验。
Eur J Drug Metab Pharmacokinet. 2025 Jul 17. doi: 10.1007/s13318-025-00956-1.
2
Evaluation of the Drug-Drug Interaction Potential of the GlyT1 Inhibitor Iclepertin (BI 425809): A Physiologically Based Pharmacokinetic (PBPK) Modeling Approach.甘氨酸转运体1（GlyT1）抑制剂依克哌汀（BI 425809）的药物相互作用潜力评估：基于生理的药代动力学（PBPK）建模方法
CPT Pharmacometrics Syst Pharmacol. 2025 Aug;14(8):1391-1402. doi: 10.1002/psp4.70060. Epub 2025 Jun 25.
3
Modulation of the human GlyT1 by clinical drugs and cholesterol.临床药物和胆固醇对人甘氨酸转运体1（GlyT1）的调节作用
Nat Commun. 2025 Mar 11;16(1):2412. doi: 10.1038/s41467-025-57613-z.
4
Commentary.评论
Schizophr Bull. 2025 Mar 14;51(2):278-282. doi: 10.1093/schbul/sbae191.
5
Efficacy and safety of iclepertin (BI 425809) with adjunctive computerized cognitive training in patients with schizophrenia.艾考必利（BI 425809）联合计算机化认知训练用于精神分裂症患者的疗效与安全性
Schizophr Res Cogn. 2024 Dec 14;40:100340. doi: 10.1016/j.scog.2024.100340. eCollection 2025 Jun.
6
Measuring Cognitive Impairments Associated With Schizophrenia in Clinical Practice: Overview of Current Challenges and Future Opportunities.在临床实践中测量与精神分裂症相关的认知障碍：当前挑战与未来机遇概述
Schizophr Bull. 2025 Mar 14;51(2):401-421. doi: 10.1093/schbul/sbae051.
7
A Patient-Clinician Discussion of Current Challenges in Schizophrenia Part 1: Addressing Daily Functioning and Cognitive Impairments Associated with Schizophrenia [Podcast].患者与临床医生探讨精神分裂症当前面临的挑战 第1部分：应对与精神分裂症相关的日常功能和认知障碍 [播客]
Neuropsychiatr Dis Treat. 2023 Jun 2;19:1331-1338. doi: 10.2147/NDT.S419177. eCollection 2023.
8
Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia.新型 GlyT1 抑制剂 iclepertin（BI 425809）的开发，用于治疗与精神分裂症相关的认知障碍。
Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1557-1566. doi: 10.1007/s00406-023-01576-z. Epub 2023 Mar 27.
9
How Functional Connectivity Measures Affect the Outcomes of Global Neuronal Network Characteristics in Patients with Schizophrenia Compared to Healthy Controls.与健康对照相比，功能连接测量如何影响精神分裂症患者全球神经元网络特征的结果。
Brain Sci. 2023 Jan 13;13(1):138. doi: 10.3390/brainsci13010138.
10
The MATRICS Consensus Cognitive Battery: An Update.MATRICS共识认知成套测验：最新情况
Curr Top Behav Neurosci. 2023;63:1-18. doi: 10.1007/7854_2022_395.
本文引用的文献
1
Nonsocial and social cognition in schizophrenia: current evidence and future directions.精神分裂症中的非社会性和社会性认知：当前证据与未来方向。
World Psychiatry. 2019 Jun;18(2):146-161. doi: 10.1002/wps.20624.
2
Indexed Pain Journals.索引疼痛期刊。
J Pain Palliat Care Pharmacother. 2008;22(1):45-46. doi: 10.1080/15360280801989377.
3
Placebo Response and Practice Effects in Schizophrenia Cognition Trials.精神分裂症认知试验中的安慰剂反应与实践效应
JAMA Psychiatry. 2017 Aug 1;74(8):807-814. doi: 10.1001/jamapsychiatry.2017.1574.
4
The MATRICS consensus cognitive battery: what we know 6 years later.精神分裂症认知功能成套测验共识版：6年后我们所了解的情况
Am J Psychiatry. 2014 Nov 1;171(11):1151-4. doi: 10.1176/appi.ajp.2014.14070936.
5
Cognition and motivation as treatment targets in schizophrenia.认知与动机作为精神分裂症的治疗靶点
JAMA Psychiatry. 2014 Sep;71(9):987-8. doi: 10.1001/jamapsychiatry.2014.1281.
6
Schizophrenia is a cognitive illness: time for a change in focus.精神分裂症是一种认知障碍：是时候改变关注焦点了。
JAMA Psychiatry. 2013 Oct;70(10):1107-12. doi: 10.1001/jamapsychiatry.2013.155.
Zotero 插件